Paper37843751
Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
Ueki Y and 15 others. Int J Clin Oncol, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma. Papers, record 37843751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37843751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Head and Neck Neoplasms | Major topic |
| Carcinoma, Squamous Cell | Major topic |
| Adult | |
| Male | |
| Humans | |
| Aged | |
| Female | |
| Cisplatin | |
| Squamous Cell Carcinoma of Head and Neck | |
| Carboplatin | |
| Prospective Studies | |
| Chemoradiotherapy | |
| Antineoplastic Combined Chemotherapy Protocols |
Source PubMed
References21
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 2 | 17467265 | Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial. | Eur J Cancer | 2007 | https://conductscience.org/library/papers/17467265 | PubMed |
| 3 | 31893516 | Head and Neck Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31893516 | PubMed |
| 4 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 5 | 35230884 | Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35230884 | PubMed |
| 6 | 23208313 | Investigation of the freely available easy-to-use software 'EZR' for medical statistics. | Bone Marrow Transplant | 2013 | https://conductscience.org/library/papers/23208313 | PubMed |
| 7 | 26712252 | Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. | Oral Oncol | 2016 | https://conductscience.org/library/papers/26712252 | PubMed |
| 8 | 29567334 | Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan. | Auris Nasus Larynx | 2018 | https://conductscience.org/library/papers/29567334 | PubMed |
| 9 | 9552032 | Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9552032 | PubMed |
| 10 | 25442075 | Chemoradiation in elderly patients with head and neck cancers: a single institution experience. | Am J Otolaryngol | 2015 | https://conductscience.org/library/papers/25442075 | PubMed |
| 11 | 36136306 | Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer. | JAMA Otolaryngol Head Neck Surg | 2022 | https://conductscience.org/library/papers/36136306 | PubMed |
| 12 | 14645636 | Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. | N Engl J Med | 2003 | https://conductscience.org/library/papers/14645636 | PubMed |
| 13 | 10758304 | The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. | Int J Radiat Oncol Biol Phys | 2000 | https://conductscience.org/library/papers/10758304 | PubMed |
| 14 | 12506176 | An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12506176 | PubMed |
| 15 | 21900218 | Esophageal and esophagogastric junction cancers. | J Natl Compr Canc Netw | 2011 | https://conductscience.org/library/papers/21900218 | PubMed |
| 16 | 26423341 | Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. | Jpn J Clin Oncol | 2015 | https://conductscience.org/library/papers/26423341 | PubMed |
| 17 | 2681557 | Carboplatin dosage: prospective evaluation of a simple formula based on renal function. | J Clin Oncol | 1989 | https://conductscience.org/library/papers/2681557 | PubMed |
| 18 | 25601342 | Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/25601342 | PubMed |
| 19 | 16467544 | Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. | N Engl J Med | 2006 | https://conductscience.org/library/papers/16467544 | PubMed |
| 20 | 22646630 | Preoperative chemoradiotherapy for esophageal or junctional cancer. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22646630 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40652131 | Oropharyngeal candidiasis during radiotherapy for head and neck cancer: an observational study on prevalence, pain, and risk factors. | Eur Arch Otorhinolaryngol | 2025 | https://conductscience.org/library/papers/40652131 | PubMed |
| 40323514 | Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data. | Int J Clin Oncol | 2025 | https://conductscience.org/library/papers/40323514 | PubMed |
| 39235658 | The role of prehabilitation in HNSCC patients treated with chemoradiotherapy. | Support Care Cancer | 2024 | https://conductscience.org/library/papers/39235658 | PubMed |
| 39093329 | Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review. | J Cancer Res Clin Oncol | 2024 | https://conductscience.org/library/papers/39093329 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37843751
GET https://conductscience.org/api/papers/v1/37843751/references?page=2